Clear blue water for Avastin in third ovarian cancer study
This article was originally published in Scrip
Executive Summary
Roche/Genentech's best-selling anticancer drug Avastin (bevacizumab) has met the primary endpoint in its third Phase III trial in ovarian cancer, giving a welcome boost in sentiment for the drug.